131 related articles for article (PubMed ID: 33545180)
1. Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model.
Akagi S; Ando H; Fujita K; Shimizu T; Ishima Y; Tajima K; Matsushima T; Kusano T; Ishida T
Int J Biol Macromol; 2021 Mar; 174():494-501. PubMed ID: 33545180
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin Embedded into Nanofibrillated Bacterial Cellulose (NFBC) Produces a Promising Therapeutic Outcome for Peritoneally Metastatic Gastric Cancer in Mice Models via Intraperitoneal Direct Injection.
Ando H; Mochizuki T; Lila ASA; Akagi S; Tajima K; Fujita K; Shimizu T; Ishima Y; Matsushima T; Kusano T; Ishida T
Nanomaterials (Basel); 2021 Jun; 11(7):. PubMed ID: 34203462
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
Soma D; Kitayama J; Konno T; Ishihara K; Yamada J; Kamei T; Ishigami H; Kaisaki S; Nagawa H
Cancer Sci; 2009 Oct; 100(10):1979-85. PubMed ID: 19604244
[TBL] [Abstract][Full Text] [Related]
5. A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.
Ando H; Fukushima M; Eshima K; Hasui T; Shimizu T; Ishima Y; Huang CL; Wada H; Ishida T
Cancer Med; 2019 Dec; 8(17):7313-7321. PubMed ID: 31609087
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
7. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.
Emoto S; Yamaguchi H; Kishikawa J; Yamashita H; Ishigami H; Kitayama J
Cancer Sci; 2012 Jul; 103(7):1304-10. PubMed ID: 22429777
[TBL] [Abstract][Full Text] [Related]
9. One-Step Production of Amphiphilic Nanofibrillated Cellulose Using a Cellulose-Producing Bacterium.
Tajima K; Kusumoto R; Kose R; Kono H; Matsushima T; Isono T; Yamamoto T; Satoh T
Biomacromolecules; 2017 Oct; 18(10):3432-3438. PubMed ID: 28876907
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
11. Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
Ohbatake Y; Fushida S; Tsukada T; Kinoshita J; Oyama K; Hayashi H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Yashiro M; Hirakawa K; Ohta T
Clin Exp Med; 2016 Nov; 16(4):585-592. PubMed ID: 26359244
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.
Kitayama J; Emoto S; Yamaguchi H; Ishigami H; Watanabe T
Cancer Chemother Pharmacol; 2014 Mar; 73(3):605-12. PubMed ID: 24464356
[TBL] [Abstract][Full Text] [Related]
14. Novel "Carrier-Free" Nanofiber Codelivery Systems with the Synergistic Antitumor Effect of Paclitaxel and Tetrandrine through the Enhancement of Mitochondrial Apoptosis.
Li X; Yu N; Li J; Bai J; Ding D; Tang Q; Xu H
ACS Appl Mater Interfaces; 2020 Mar; 12(9):10096-10106. PubMed ID: 32027119
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.
Simón-Gracia L; Hunt H; Scodeller PD; Gaitzsch J; Braun GB; Willmore AM; Ruoslahti E; Battaglia G; Teesalu T
Mol Cancer Ther; 2016 Apr; 15(4):670-9. PubMed ID: 26880267
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
Ohashi N; Kodera Y; Nakanishi H; Yokoyama H; Fujiwara M; Koike M; Hibi K; Nakao A; Tatematsu M
Int J Oncol; 2005 Sep; 27(3):637-44. PubMed ID: 16077911
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer.
De Clercq K; Xie F; De Wever O; Descamps B; Hoorens A; Vermeulen A; Ceelen W; Vervaet C
Sci Rep; 2019 Oct; 9(1):14881. PubMed ID: 31619730
[TBL] [Abstract][Full Text] [Related]
18. Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice.
Xie F; De Clercq K; Vervaet C; Van Bocxlaer J; Colin P; Vermeulen A
Pharm Res; 2019 Jun; 36(9):127. PubMed ID: 31236836
[TBL] [Abstract][Full Text] [Related]
19. High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.
Coccolini F; Acocella F; Morosi L; Brizzola S; Ghiringhelli M; Ceresoli M; Davoli E; Ansaloni L; D'Incalci M; Zucchetti M
Pharm Res; 2017 Jun; 34(6):1180-1186. PubMed ID: 28247168
[TBL] [Abstract][Full Text] [Related]
20. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
